DUBLIN--(BUSINESS WIRE)--The "Bioprocess Validation - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Bioprocess Validation Market to Reach $622.6 Million by 2030
The global market for Bioprocess Validation estimated at US$370.1 Million in the year 2023, is projected to reach a revised size of US$622.6 Million by 2030, growing at a CAGR of 6.7% over the analysis period 2023-2030. Extractables / Leachables Testing Services, one of the segments analyzed in the report, is projected to record 7.3% CAGR and reach US$255.6 Million by the end of the analysis period. Growth in the Integrity Testing Services segment is estimated at 6.7% CAGR for the next 8-year period.
Process validation is a critical aspect of ensuring the safety and efficacy of pharmaceutical products. There are various types of process validation, including prospective, concurrent, retrospective, and revalidation. Each type serves a specific purpose in confirming that manufacturing processes consistently produce products meeting predetermined quality criteria.
The global market outlook for process validation services is positive, with extractables/leachables testing services emerging as the largest segment. Developed regions currently lead the market, but developing economies hold significant promise for future growth. This is driven by increasing investments in the pharmaceutical and biotech sectors, which necessitate comprehensive validation services to prevent product contamination and ensure regulatory compliance.
The bioprocess validation market is competitive, with key global players holding notable market shares projected for 2024. Recent market activities highlight rapid growth in biopharmaceutical production, further emphasizing the need for robust validation services. The rise of pharmaceutical contract manufacturing presents additional growth opportunities, particularly for bioprocess validation outsourcing to emerging markets.
As pharma and biotech companies continue to invest heavily in drug development activities, the demand for bioprocess validation services is expected to rise. This trend underscores the importance of maintaining stringent validation protocols to support the increasing complexity and scale of modern pharmaceutical manufacturing.
The U.S. Market is Estimated at $135.8 Million, While China is Forecast to Grow at 9.4% CAGR
The Bioprocess Validation market in the U.S. is estimated at US$135.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$80.8 Million by the year 2030 trailing a CAGR of 9.4% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 6% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 385 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $370.1 Million |
| Forecasted Market Value (USD) by 2030 | $622.6 Million |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
MARKET OVERVIEW
- Global Economic Update
- An Introduction to Bioprocess Validation
- Types of Process Validation
- Global Market Outlook
- Extractables/Leachables Testing Services: The Largest Segment
- Developed Regions Lead, Developing Economies Promise Future Growth
- Competition
- Bioprocess Validation - Global Key Competitors Percentage Market Share in 2024 (E)
- Recent Market Activity
MARKET TRENDS & DRIVERS
- Rapid Growth in Biopharmaceutical Production and Need to Prevent Product Contamination Necessitate Validation Services
- Increasing Pharma & Biotech Investments into Drug Development Activities Fuel Need for Bioprocess Validation
- Rise of Pharma Contract Manufacturing Present Growth Opportunities for Bioprocess Validation Outsourcing to Emerging Markets
- Global Pharmaceutical Contract Manufacturing Market by Geographic Region for 2021 and 2027
- Biosimilars Gain from Patent Expiry of Major Drugs, Driving Gains for Bioprocess Validation Market
- Strict Safety & Quality Regulations and Compliance with cGMP for Biopharmaceuticals Support Market Growth
- Bioprocessing 4.0: Implications for Bioprocess Validation
- Validation 4.0: Essential for Sciences Industry Progresses towards Digital-First Industry
- Growing Prominence of Paperless Validation in Pharma, Biotech & Medical Devices Industries
- Bioprocess Innovations Direct Focus onto Effective & Clear Validations
- Digital Twins to Support Bioprocess Validation Market Growth
- AI-Enabled System-Led Transformations in Biomanufacturing & Bioprocess Validation
- Artificial Intelligence and Continuous Validation
- Single-Use Disposable Technologies Gain Attention
- Bioprocess Data: Critical for Improving Efficiency of Pharma Developments & Manufacturing Operations
- Advancing Process Analytical Technologies Necessitates Validation
- Process Validation for Viral Vectors: What are the Key Challenges?
- Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market Growth
- Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
- Challenges Confronting Bioprocess Validation
FOCUS ON SELECT PLAYERS (Total 50 Featured)
- Almac Group
- Bangalore Biotech Labs Pvt Ltd (Biozeen)
- DOC S.r.l
- Eurofins Scientific SE
- Hangzhou Cobetter Filtration Equipment Co. Ltd.
- Lonza Group AG
- Meissner Filtration Products, Inc.
- Merck KGaA
- Pall Corporation, a subsidiary of Danaher Corporation
- Porvair Plc
- Sartorius AG
- SGS S.A.
- Thermo Fisher Scientific, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/98cyk0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
